Trilaciclib was found to to be a promising new treatment for chemotherapy-induced myelosuppression prevention and other benefits for patients with extensive-stage small cell lung cancer.
Treatment with trilaciclib (Cosela) may lower cases of single and multilineage grade 3 myelosuppressive hematologic adverse events (HAEs) as well as cytopenia-related healthcare utilization in patients with extensive-stage small cell lung cancer (ES-SCLC), real-world evidence shows.1
"Our study evaluated real-world outcomes of patients using data from published and unpublished studies of trilaciclib and comparable non-trilaciclib-treated patients," said Lowell Hart, MD, FACP, a medical oncologist/hematologist at Florida Cancer Specialists & Research Institute, in a press release.2 "We found this therapy to be a promising new treatment for chemotherapy-induced myelosuppression (CIM) prevention and with the potential for additional benefits."
In total, 5 studies were reviewed after being accessed through 8 records, including the iKM network, non-iKM networks, Florida Cancer Specialist & Research Institute (FCS), and Integra Connect. A total 137 patients were included in the pooled data.
Results showed that the weighted average prevalence of grade ≥ 3 myelosuppressive HAEs in patients with ≥ 1 lineage was 40.5%. Among patients with ≥ 2 lineages, the prevalence of grade ≥ 3 myelosuppressive HAEs was 14.5%. In patients with all 3 lineages, the prevalence of grade ≥ 3 myelosuppressive HAEs was 7.5%. The rates in all 3 cohorts were numerically better than historic controls in non-trilaciclib cohorts, which respectively showed a prevalence of 58.5%, 28.0%, and 13.0%.
Further, 43.8% of patients had cytopenia-related healthcare utilization. The most common form of healthcare utilization was the receipt of IV hydration, which all patients needed. Patients also required red blood cell transfusions (15.3%), platelet transfusions (0.7%), and erythropoietin stimulating agents (19.7%).
The findings suggest that trilaciclib (Cosela) before administering topotecan can improve chemotherapy outcomes. These findings are consistent with data from clinical trials, which demonstrate the dexterity of trilaciclib in ES-SCLC. Hart et al believe comparative studies with a larger number of patients are needed to provide more in-depth information about the effectiveness of trilaciclib in ES-SCLC.
"FCS continues to be at the forefront of game-changing clinical discoveries that are bringing new hope for cancer patients,” Lucio Gordon, MD, president and managing physician at FCS, in the press release.2 "The size of our practice, having nearly 100 locations, is a large contributor to the research being conducted by our physicians, providing a generous pool of patients and data, a pillar in our continued efforts to advance oncology care."
1. Goldschmidt J, Hart L, Scott J, et al. Real-World outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy. Adv Ther. Published July 25, 2023. doi: 10.1007/s12325-023-02601-2.
2. Study confirms effectiveness of trilaciclib for treatment of patients with extensive-stage small cell lung cancer co-authored by Florida Cancer Specialists & Research Institute physicians and senior leaders. News release. July 31, 2023. Accessed September 8, 2023. https://tinyurl.com/2p8d5uce